×
About 148,500 results

RECOVER Researchers Express Hope and Frustration in Their Study of Long COVID
https://www.medpagetoday.com/special-reports/exclusives/99403
MedPage Today; DePeau-Wilson M.

Jul 23rd, 2022 - Slow enrollment has led to simmering frustrations over the progress and potential of the NIH's RECOVER Initiative, the research consortium focused on studying post-acute sequelae of SARS-CoV-2, or long COVID, according to researchers and leaders within the initiative. The RECOVER Initiative was designed to support research on long COVID across the U.S., including among every group of people ...

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
https://www.biorxiv.org/content/10.1101/2022.10.24.513619v1
BioRxiv Collier AY, .

Oct 25th, 2022 - Waning immunity following mRNA vaccination and the emergence of SARS-CoV-2 variants has led to reduced mRNA vaccine efficacy against both symptomatic infection and severe disease. Bivalent mRNA boosters expressing the Omicron BA.5 and ancestral WA1/2020 Spike proteins have been developed and approved, because BA.5 is currently the dominant SARS-CoV-2 variant and substantially evades neutralizin...

Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot
https://www.biorxiv.org/content/10.1101/2022.10.22.513349v1
BioRxiv Wang Q, .

Oct 24th, 2022 - The SARS-CoV-2 Omicron variant and its numerous sub-lineages have exhibited a striking ability to evade humoral immune responses induced by prior vaccination or infection. The Food and Drug Administration (FDA) has recently granted Emergency Use Authorizations (EUAs) to new bivalent formulations of the original Moderna and Pfizer mRNA SARS-CoV-2 vaccines that target both the ancestral strain as...

NFATc2-dependent Epigenetic Downregulation of the TSC2/Beclin-1 Pathway is Involved in ...
https://doi.org/10.1177/17448069231158289
Molecular Pain; Liu M, Mai JW et. al.

Feb 4th, 2023 - Neuropathic pain is a common dose-limiting side effect of oxaliplatin, which hampers the effective treatment of tumors. Here, we found that upregulation of transcription factor NFATc2 decreased the expression of Beclin-1, a critical molecule in autophagy, in the spinal dorsal horn, and contributed to neuropathic pain following oxaliplatin treatment. Meanwhile, manipulating autophagy levels by i...

Anticancer Phytochemical-Based Nanoformulations: Therapeutic Intervention in Cancer Cel...
https://doi.org/10.1615/JEnvironPatholToxicolOncol.2022044317
Journal of Environmental Pathology, Toxicology and Oncolo... Talukdar D, Kumar P et. al.

Feb 4th, 2023 - Phytochemicals have the potential to treat resistant cancer. They are delivered to the target site via nano-based carriers. Promising results are seen in preclinical and in vitro models, as phytochemical-based nanoformulations have improved cell cytotoxicity compared to single agents. They can synergistically inhibit cancer cell growth through p53 apoptosis in MCF-7 breast cancer cell lines. Mo...

Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: outcomes of a ded...
https://doi.org/10.1007/s00464-023-09896-w
Surgical Endoscopy; Morrell DJ, Chau MH et. al.

Feb 4th, 2023 - Patients requiring percutaneous endoscopic gastrostomy (PEG) for amyotrophic lateral sclerosis (ALS) related dysphagia represent a clinical challenge. Diminished pulmonary function and aspiration risks can lead to anesthesia-related complications, and gastric displacement from hemidiaphragm elevation may preclude safe gastric access. This study reports the efficacy and outcomes of a dedicated a...

Gracilis Muscle Interposition for the Treatment of Rectovaginal Fistula: A Systematic R...
https://doi.org/10.1097/DCR.0000000000002739
Diseases of the Colon and Rectum; Maspero M, Otero Piñeiro A et. al.

Feb 4th, 2023 - A rectovaginal fistula is a debilitating condition that often severely impacts quality of life. Despite many treatment options available, the best surgical treatment is far from being established and many patients will undergo several procedures before fistula closure is achieved. Gracilis muscle interposition, i.e. the transposition of the gracilis muscle into the rectovaginal septum, is an op...

Mutation of FLNA attenuating the migration of abdominal muscles contributed to Melnick-...
https://doi.org/10.1002/mgg3.2145
Molecular Genetics & Genomic Medicine; Luo X, Yang Z et. al.

Feb 4th, 2023 - Filamin A, encoded by the X-linked gene FLNA, links the cell membrane with the cytoskeleton and acts as a regulator of the actin cytoskeleton. Mutations in FLNA cause a large spectrum of congenital malformations during embryonic development, including Melnick-Needles syndrome (MNS). However, reports of MNS, especially in males, are rare, and the pathogenesis molecular mechanisms are not well un...

Methods of tissue preparation after EUS-guided tissue acquisition without rapid on-site...
https://doi.org/10.1111/jgh.16137
Journal of Gastroenterology and Hepatology; Phan VA, Ruszkiewicz A et. al.

Feb 4th, 2023 - In the absence of rapid on-site evaluation (ROSE), it is not clear which method of tissue preparation is best to process tissue obtained from EUS-guidance. Cytological-smearing (CS), cell-block (CB) and direct-histology (DH) are the available techniques AIM: To compare the diagnostic yield of 3 techniques of tissue preparation for EUS-guided tissue acquisition without ROSE. Patients who were re...

BCG Vaccine Flops for Preventing COVID, Other Respiratory Infections
https://www.medpagetoday.com/infectiousdisease/covid19/102958

Feb 3rd, 2023 - The bacillus Calmette-Guérin (BCG) vaccine failed to protect against COVID-19 and other respiratory tract infections (RTIs) among older adults with comorbidities, according to a randomized trial from The Netherlands. In a group of older patients with a median of two comorbidities, COVID infections were reported in 4.2% patients who received the BCG vaccine compared with 3.7% of those given plac...

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04669171

Feb 3rd, 2023 - EO2463 Is an innovative cancer peptide therapeutic vaccine based on the homologies between tumor associated antigens and microbiome-derived peptides that will be administered alone and in combination with lenalidomide, rituximab, and lenalidomide/rituximab to generate safety and preliminary efficacy data in patients with indolent NHL

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent H...
https://clinicaltrials.gov/ct2/show/NCT04671667

Feb 3rd, 2023 - PRIMARY OBJECTIVES: I. To evaluate overall survival (OS) of adjuvant reirradiation plus concurrent pembrolizumab followed by pembrolizumab to complete 12 months total of pembrolizumab to adjuvant reirradiation plus concurrent platinum chemotherapy in high risk head and neck squamous cell carcinoma (HNSCC) patients. II. To evaluate OS of adjuvant pembrolizumab for 12 months compared to adjuvant ...

Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
https://clinicaltrials.gov/ct2/show/NCT04535414

Feb 3rd, 2023 - Background: Hereditary Diffuse Gastric Cancer (HDGC) is most often attributed to inactivating germline mutations in the E-cadherin (CDH1) tumor suppressor gene. Mutation carriers have a 24-70% lifetime risk of developing gastric adenocarcinoma. International consensus guidelines recommend endoscopic screening and surveillance of CDH1 mutation carriers who decline risk-reducing total gastrectomy...

Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
https://clinicaltrials.gov/ct2/show/NCT04441710

Feb 3rd, 2023 - Hospital mortality attributed to SARS-CoV-2 in France increased daily by 28% in the week before confinement. The week following this decision, the daily increase was 30%. During the week of the second week of confinement, it started a decline of 19% estimated over the last 5 days, reaching the cumulative number of 2606 deaths on 29/3 (site https://www.eficiens.com/coronavirus- personal statisti...

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT02769962

Feb 3rd, 2023 - Background: Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis. Although highly responsive to chemotherapy initially, SCLC relapses quickly and becomes refractory to treatment within a few months. Urothelial Carcinoma (UC) of the Bladder is the fourth most common malignancy in men and the ninth most common in women. Prostate cancer is the most common cancer among men in...

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)
https://clinicaltrials.gov/ct2/show/NCT04453839

Feb 3rd, 2023 - 5. INTRODUCTION 5.1 Executive Summary ZYESAMI (aviptadil) is a synthetic form of Vasoactive Intestinal Polypeptide (VIP), a ubiquitous, naturally synthesized human peptide with extensively documented anti-inflammatory, anti-cytokine cascade properties. It has been granted FDA Fast Track Designation for treatment of Critical COVID-19 with Respiratory Failure. A phase 2/3 trial is underway that h...

Anthrax AV7909 Liquid vs Lyophilized
https://clinicaltrials.gov/ct2/show/NCT04660201

Feb 3rd, 2023 - This is a randomized, parallel-group, double-blind, Phase 1 study designed to assess safety, tolerability and immunogenicity of 2 formulations of adjuvanted anthrax vaccine (AV7909), lyophilized and liquid. Forty healthy young adults, 18 to 45 years old, inclusive, who meet all eligibility criteria, will be randomly allocated to one of two study groups in a 1:1 ratio: 20 will receive AV7909 as ...

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
https://clinicaltrials.gov/ct2/show/NCT01799538

Feb 3rd, 2023 - We have reported that approximately one third of patients with lymphangioleiomyomatosis (LAM) who have airflow obstruction respond to bronchodilators such as albuterol, a Beta2-adenergic receptor agonist, with an increase in forced expiratory flow in one second (FEV1) of 12% and 200 ml above baseline values. Others however, have questioned these findings, reporting instead, a low rate of respon...

Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00848328

Feb 3rd, 2023 - OBJECTIVES: Primary To determine the response rate in patients with relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphoma treated with lenalidomide and rituximab. Secondary To determine the time to disease progression, duration of response, and overall survival of these patients. To determine the tolerability of this regimen in these patients. To assess changes in serum cy...

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01829568

Feb 3rd, 2023 - PRIMARY OBJECTIVE: I. To determine the recommended phase II doses of ibrutinib and lenalidomide for combination with rituximab in previously untreated follicular lymphoma. SECONDARY OBJECTIVES: I. To determine pharmacokinetics of ibrutinib and its major metabolite (PCI-45227) when combined with lenalidomide and rituximab. II. To determine the pharmacodynamics of basophil activation and Bruton t...